Celgene (NASDAQ:CELG) is a company that doesn't stop impressing. This company is a beacon of hope for society as few companies are making so much progress in treating cancer as Celgene. Investors who are passionate about putting their money on companies with strong values should feel very comfortable owning shares of Celgene. And for those seeking companies which are likely to outperform the S&P for the next decade, this company is currently at an inflection point which will propel it much higher. We are targeting a $196 price on Celgene sometime on 2019. We will give investors some reasons for our analysis. We also recommend investors to listen to the Celgene Presentation at the 35th Annual J.P. Morgan Healthcare Conference.
Valuation:
Celgene has a very cheap forward P/E valuation of 17.04. That's the standard valuation for the S&P Celgene raised its guidance to a range of $7.10-7.25 for 2017, compared to its previous estimate of $6.75-7 during the J.P. Morgan Healthcare Conference.
